{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    8,
    37,
    44,
    47,
    54,
    57,
    59
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schema Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2",
        "sectionTitle": "Schema",
        "description": "Reference to study schema for primary endpoint analysis"
      },
      {
        "id": "ref_2",
        "name": "Study Design Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Study Design",
        "description": "Reference to overall study design regarding primary analysis data cut-off"
      },
      {
        "id": "ref_3",
        "name": "Statistical Hypotheses Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1",
        "sectionTitle": "Statistical Hypotheses",
        "description": "Reference to primary endpoint events and power calculations"
      },
      {
        "id": "ref_4",
        "name": "Sample Size Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2",
        "sectionTitle": "Sample Size Determination",
        "description": "Reference to reduction in statistical power and event requirements"
      },
      {
        "id": "ref_5",
        "name": "Inclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference for contraceptive methods in medication summary table"
      },
      {
        "id": "ref_6",
        "name": "Hospitalization Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix H",
        "sectionTitle": "Hospitalization Definition",
        "description": "Guidance on the definition of hospitalization for exclusion criteria"
      },
      {
        "id": "ref_7",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities for Cohort 1",
        "description": "Reference for timing of injection site inspections and AESI collection"
      },
      {
        "id": "ref_8",
        "name": "Liver Biochemistry Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix D",
        "sectionTitle": "Actions Required in Cases of Increases in Liver Biochemistry and Evaluation of Hy’s Law",
        "description": "Instructions for handling elevated AST, ALT, or TBL levels"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The potential impact of AZD7442 on COVID-19 vaccines is not known and has not been studied.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Summary of Permitted, Prohibited, or Restricted Medications",
        "pageNumber": 45
      },
      {
        "id": "annot_2",
        "text": "In case a participant shows an AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN please refer to Appendix D.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Coagulation",
        "pageNumber": 55
      },
      {
        "id": "annot_3",
        "text": "Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of the study.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Inclusion Criteria",
        "pageNumber": 38
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "7.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-06-30",
        "description": "Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442",
        "amendmentNumber": "Amendment 6"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 3,
      "versionCount": 1
    }
  }
}